



PRESS RELEASE

Published: 23-08-2023

Inhalation Sciences AB (publ) to repay its loan by end of August 2023

(Stockholm, Sweden, 23 August 2023) **Inhalation Sciences AB will repay a 1.8 MSEK loan which was reported in the Q1 Report 2023. The loan will be repaid by the end of August 2023. The contractual due date for repayment is December 2023. The total amount including interest and setup fee is approx. 2.6 MSEK.**

In the Q1 Report (31 May 2023) ISAB reported that on January 16th, 2023 it had activated 1.8 MSEK of its credit facility, due to be repaid in December 2023. ISAB will now in advance repay the loan by the end of August 2023. The total loan amount is approx. 2.6 MSEK, including interest and setup fee. By the advanced repayment, the company will save approximately 200 KSEK in interest costs.

CEO Manoush Masarrat: "The early repayment reflects our current cash balance that has been strengthened by a good inflow of awarded customer contracts and in addition with the recent completed share issue. We feel comfortable repaying this loan now instead of waiting until December due to a satisfactory cash position, as well as achieving a saving of 200 KSEK on the interest".

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.